3 results
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
The primary objective of the ADFICE_IT study is to investigate the effects of a CDSS and patient portal for optimizing FRID withdrawal on injurious falls. This study has three secondary objectives. First, we will investigate the effect of the CDSS…
To determine whether dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of kidney failure, hospitalization for heart failure, and all-cause mortality in the overall patient group, consisting of patients…